Ziccums affärsidé är att utveckla nya beredningar av biologiska läkemedel genom bolagets patenterade teknologi LaminarPace, som utvecklar torra beredningsformer av produkter som i nuläget enbart finns i vätskeform.
Bransch: Sjukvård Marknad: First North Stockholm Tickerkod: ZICC Certified Adviser: Erik Penser Bank
I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.
Omsättning
Aktuell Kurs
Utvecklingen i dag
Analyser | 27 Jan 2023 | Ziccum
ZICCUM AB (publ) Year-end report Q4 2022…
YEAR-END REPORT Q4 2022: 1 JANUARY – 31 DECEMBER 2022 To read the digital Report, please click here: https://reports-en.ziccum.com/year-end-report-q4-2022/start/ Significant events in Q4 (October – December) On October 24,…
Ziccum AB (publ) (‘Ziccum’) has now submitted its Expression of Interest application for CEPI’s Call for Proposals for funding of innovations that improve vaccine thermostability. The Coalition for Epidemic Preparedness…
Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company’s unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 – 26 January.…
Ziccum AB has been awarded non-dilutive funding of 10 MSEK by Eurostars for a joint application with the Institute of Computational Physics (ICP) at the School of Engineering at Zurich…
Lund, Nov 14, 2022 —Ziccum AB (publ) (‘Ziccum’) has launched a new website, developed in partnership with the Chords Agency in Malmö. With a new brand platform, the expanded site…
Ziccum AB has signed an agreement contracting the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’ School of Engineering (ZHAW) for the next phase of the…
Ziccum har haft ett mycket produktivt kvartal, med avsevärda framsteg inom de tre fokusområdena: Partnering, Teknologiutveckling och Förstudien för mRA/LNP-plattformen. Ann Gidner, Ziccums nya VD som tillträdde i maj månad…
INTERIM REPORT Q3 2022: 1 JANUARY – 30 SEPTEMBER 2022. To read the digital Report, please click here: https://reports-en.ziccum.com/interim-report-q3-2022/start/ Significant events during Q3 (July-September) On July 19, Ziccum published the…
ZICCUM AB (publ) has generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in its in-house mRNA project. This was carried out using LaminarPaceTM, the company’s ambient…
Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will…
Kommande händelser